Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732833 · ClinicalTrials.gov registry record · Phase 3
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
A Phase 3 study of Lateral Canthal Lines and Glabellar Lines, sponsored by Medy-Tox.
- Completed
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
- 20
- Study locations
NCT03732833 is a Phase 3 study of Lateral Canthal Lines and Glabellar Lines that has completed, run by Medy-Tox. The registered enrollment target is 425 participants, above the 268-participant average among 5 other Lateral Canthal Lines trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03732833, a Phase 3 study of Lateral Canthal Lines and Glabellar Lines, has completed, sponsored by Medy-Tox.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT10109L
Study Locations (20)
Other
- Hautzentrum Koln - Cologne Dermatology - Cologne
- Hautok and Hautok-cosmetics - München
- MediCorium Zentrum fuer Dermatologie und Aesthetik - Oberursel
- CentroDerm GmbH - Wuppertal
New York
- Dermatology and Laser Surgery Center of New York - New York
- Skin Search of Rochester Inc. - Rochester
North Carolina
- M3 Wake Research Inc. - Raleigh
- Wilmington Dermatology Center - Wilmington
Texas
- Westlake Dermatology & Cosmetic Surgery - Westlake - Austin
- DermResearch Inc. - Austin
British Columbia
- Dr. Jean Carruthers Cosmetic Surgery Inc. - Vancouver
- Pacific Derm - Vancouver
Ontario
- Dermetics Cosmetic Dermatology - Burlington
- Nectar Research Group Inc. - Richmond Hill
Arizona
- Clear Dermatology & Aesthetics Center - Scottsdale
California
- Art of Skin MD - Solana Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732833
The ClinicalTrials.gov registry entry for NCT03732833 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 5 other Lateral Canthal Lines trials with a reported enrollment target (59% higher). The listed sponsor is Medy-Tox, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lateral Canthal Lines appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03732833 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03732833 about?
NCT03732833 is a clinical study titled "MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines". To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.
What is the current status of trial NCT03732833?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2018-11-05. Estimated completion is 2021-01-25.
What conditions does trial NCT03732833 study?
This clinical trial studies the following conditions: Lateral Canthal Lines, Glabellar Lines.
What interventions are being tested in trial NCT03732833?
The interventions under investigation include: Placebo (DRUG), MT10109L (DRUG).
Who is sponsoring clinical trial NCT03732833?
This trial is sponsored by Medy-Tox, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03732833 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lateral Canthal Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
COMPLETED · Phase 3
-
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
COMPLETED · Phase 2
-
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.